Q1 EPS Forecast for X4 Pharmaceuticals Increased by Analyst

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for X4 Pharmaceuticals in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.02) per share for the quarter, up from their previous estimate of ($0.15). HC Wainwright has a “Buy” rating and a $1.50 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.32) EPS, FY2026 earnings at ($0.23) EPS and FY2027 earnings at ($0.16) EPS.

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $3.00 price target on shares of X4 Pharmaceuticals in a report on Wednesday, March 26th.

X4 Pharmaceuticals Stock Performance

Shares of X4 Pharmaceuticals stock opened at $0.22 on Monday. The business has a fifty day simple moving average of $0.42 and a two-hundred day simple moving average of $0.51. The firm has a market capitalization of $38.50 million, a P/E ratio of -2.46 and a beta of 0.39. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.43 million for the quarter, compared to analysts’ expectations of $1.07 million.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO Adam S. Mostafa sold 74,773 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Paula Ragan sold 76,473 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at $489,323.70. This trade represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 202,663 shares of company stock valued at $91,198. 1.62% of the stock is owned by insiders.

Institutional Trading of X4 Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC purchased a new stake in X4 Pharmaceuticals in the fourth quarter worth $5,363,000. Geode Capital Management LLC grew its holdings in shares of X4 Pharmaceuticals by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 3,497,212 shares of the company’s stock worth $2,566,000 after purchasing an additional 49,700 shares during the last quarter. State Street Corp increased its stake in X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after buying an additional 189,105 shares during the period. Northern Trust Corp lifted its holdings in X4 Pharmaceuticals by 2.9% during the 4th quarter. Northern Trust Corp now owns 1,357,539 shares of the company’s stock valued at $996,000 after buying an additional 37,940 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in X4 Pharmaceuticals by 4.0% in the 4th quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock valued at $477,000 after buying an additional 24,948 shares during the period. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.